Do Thrombophilias Cause Placenta-Mediated Pregnancy Complications?

ABSTRACT

There has been an sudden increase of knowledge about thrombophilias in the last decade as new thrombophilias are discovered and new associations are explored. It is now evident that thrombophilias are common and that the clinical consequences of having a thrombophilia do not appear to be limited to venous thromboembolism. The placenta-mediated pregnancy complications are also common (more than one in six pregnancies are affected) and include pregnancy loss, preeclampsia, placental abruption, and intrauterine growth restriction. These complications as a whole are the leading causes of maternal and neonatal morbidity in the developed world. Evidence has emerged to suggest that thrombophilic women may be at higher risk of developing these placenta-mediated pregnancy complications. However, is this evidence mature enough to claim that a causal association is proven? Is the evidence strong enough to recommend anticoagulant prophylaxis? We suggest that causality is not yet proven and that the data to support management with anticoagulant prophylaxis in thrombophilic pregnancies is too immature to consider this an established intervention.

KEYWORDS

Thrombophilia - intrauterine growth restriction (IUGR) - preeclampsia - pregnancy loss - placental abruption

REFERENCES

• 1 van der Meer F J, Koster T, Vandenbroucke J P, Briet E, Rosendaal F R. The Leiden Thrombophilia Study (LETS).  Thromb Haemost. 1997;  78 631-635
• 2 Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis project.  Thromb Haemost. 1997;  78(1) 636-640
• 3 Souto J C, Coll I, Llobet D et al.. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population.  Thromb Haemost. 1998;  80 366-369
• 4 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene.  Br J Haematol. 1997;  98 907-909
• 5 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
• 6 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of DVT.  Lancet. 1995;  345 152-155
• 7 Kraaijenhagen R A, Anker P S, Koopman M MW et al.. High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism.  Thromb Haemost. 2000;  83(1) 5-9
• 8 Halbmayer W M, Haushofer A, Schon R et al.. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors.  Thromb Haemost. 1994;  71 68-72
• 9 den Heijer M, Koster T, Blom H J et al.. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med. 1996;  334(12) 759-762
• 10 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.  JAMA. 1997;  277 1305-1307
• 11 Department of Health WO, Scottish Department of Health .Why mothers die. Report on confidential enquiries into maternal deaths in the United Kingdom 1994-1996. Drife J, Lewis G London; The Stationary Office 1998
• 12 Berg C J, Atrash H K, Koonin L M, Tucker M. Pregnancy-related mortality in the United States, 1987-1990.  Obstet Gynecol. 1996;  88 161-167
• 13 Rusen I D, Liston R, Wen S W, Bartholomew S. Special Report on Maternal Mortality and Severe Morbidity in Canada Enhanced Surveillance: The Path to Prevention. Cat. No. H39-4/44-2004E. Minister of Public Works and Government Services Canada 2004
• 14 Helewa M E, Burrows R F, Smith J, Williams K, Brain P, Rabkin S W. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy.  CMAJ. 1997;  157 715-725
• 15 Strauss R S. Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort.  JAMA. 2000;  283 625-632
• 16 Ghidini A, Salafia C M, Pezzullo J C. Placental vascular lesions and likelihood of diagnosis of preeclampsia.  Obstet Gynecol. 1997;  90(4 pt 1) 542-545
• 17 Salafia C M, Vintzileos A M, Silberman L, Bantham K F, Vogel C A. Placental pathology of idiopathic intrauterine growth retardation at term.  Am J Perinatol. 1992;  9(3) 179-184
• 18 Salafia C M, Ernst L M, Pezzullo J C, Wolf E J, Rosenkrantz T S, Vintzileos A M. The very low birthweight infant: maternal complications leading to preterm birth, placental lesions, and intrauterine growth.  Am J Perinatol. 1995;  12(2) 106-110
• 19 Salafia C M, Pezzullo J C, Lopez-Zeno J A, Simmens S, Minior V K, Vintzileos A M. Placental pathologic features of preterm preeclampsia.  Am J Obstet Gynecol. 1995;  173(4) 1097-1105
• 20 Isermann B, Sood R, Pawlinski R et al.. The thrombomodulin-protein C system is essential for the maintenance of pregnancy.  Nat Med. 2003;  9(3) 331-337
• 21 Li W, Zheng X, Gu J M et al.. Extraembryonic expression of EPCR is essential for embryonic viability.  Blood. 2005;  106(8) 2716-2722
• 22 Evans A S. Causation and disease: a chronological journey. The Thomas Parran Lecture.  Am J Epidemiol. 1978;  108(4) 249-258
• 23 Parascandola M, Weed D L. Causation in epidemiology.  J Epidemiol Community Health. 2001;  55(12) 905-912
• 24 Hill A B. The environment and disease: association or causation?.  Proc R Soc Med. 1965;  58 295-300
• 25 Thygesen L C, Andersen G S, Andersen H. A philosophical analysis of the Hill criteria.  J Epidemiol Community Health. 2005;  59(6) 512-516
• 26 Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis.  Obstet Gynecol. 2005;  105(1) 182-192
• 27 Wu O, Robertson L, Twaddle S et al.. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.  Health Technol Assess. 2006;  10 1-110
• 28 Howley H E, Walker M, Rodger M A. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction.  Am J Obstet Gynecol. 2005;  192 694-708
• 29 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.  Eur J Obstet Gynecol Reprod Biol. 2002;  101(1) 6-14
• 30 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis.  Lancet. 2003;  361(9361) 901-908
• 31 Burke W, Thomson E, Khoury M J et al.. Hereditary hemochromatosis. Gene discovery and its implications for population-based screening.  JAMA. 1998;  280 172-178
• 32 Infante-Rivard C, Rivard G E, Yotov W V et al.. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction.  N Engl J Med. 2002;  347(1) 19-25
• 33 Meinardi J R, Middeldorp S, de Kam P J et al.. Increased risk for fetal loss in carriers of the factor V Leiden mutation.  Ann Intern Med. 1999;  130 736-739
• 34 Preston F E, Rosendaal F R, Walker I D et al.. Increased fetal loss in women with heritable thrombophilia.  Lancet. 1996;  348 913-916
• 35 Redman C W. Current topic: pre-eclampsia and the placenta.  Placenta. 1991;  12(4) 301-308
• 36 Kramer M S. Determinants of low birth weight: methodological assessment and meta-analysis.  Bull World Health Organ. 1987;  65(5) 663-737
• 37 Hills F A, Abrahams V M, Gonzalez-Timon B et al.. Heparin prevents programmed cell death in human trophoblast.  Mol Hum Reprod. 2006;  12(4) 237-243
• 38 Huhle G, Geberth M, Hoffmann U, Heene D L, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.  Gynecol Obstet Invest. 2000;  49(1) 67-69
• 39 Lepercq J, Conard J, Borel-Derlon A et al.. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.  BJOG. 2001;  108 1134-1140
• 40 Greer I A, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.  Blood. 2005;  106 401-407
• 41 Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial.  Br J Obstet Gynaecol. 1983;  90(12) 1124-1128
• 42 Greer I A. The use of LMWH in pregnancies at risk: new evidence or perception?.  J Thromb Haemost. 2005;  3 781-782
• 43 Gates S, Brocklehurst P, Ayers S, Bowler U. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.  Am J Obstet Gynecol. 2004;  191 1296-1303
• 44 McColl M D, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78(4) 1183-1188
• 45 Bates S M, Greer I A, Hirsh J, Ginsberg J S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3 suppl) 627S-644S
• 46 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 47 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174(5) 1584-1589
• 48 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
• 49 Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.  Cochrane Database Syst Rev. 2005;  (2) CD002859
• 50 Gris J-C, Mercier E, Quéré I et al.. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.  Blood. 2004;  103 3695-3699
• 51 Rodger M. Important publication missing key information.  Blood. 2004;  104(10) 3413-3414
• 52 Di Nisio M, Peters L, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome.  Cochrane Database Syst Rev. 2005;  (2) CD004734
• 53 Walker M C, Ferguson S E, Allen V M. Heparin for pregnant women with acquired or inherited thrombophilias.  Cochrane Database Syst Rev. 2003;  (2) CD003580